Abate-Shen
Corinne Abate-Shen, New York, NY US
Patent application number | Description | Published |
---|---|---|
20150309036 | Diagnostic Markers of Indolent Prostate Cancer - A 3-gene prognostic panel has been identified that together accurately predicted the outcome of low Gleason score prostate tumors as either truly indolent or at a high risk of becoming aggressive. The 3-gene prognostic panel was validated on independent cohorts confirmed its independent prognostic value, as well as its ability to improve prognosis with currently used clinical nomograms. Expression of the 3-gene prognostic panel was determined by quantifying mRNA or protein encoded by the panel (collectively referred to as “prognostic biomarkers”). The prognostic biomarkers were discovered to be up-regulated in indolent tumors and down-regulated in aggressive forms of prostate cancer. | 10-29-2015 |
Corinne T. Abate-Shen, New York, NY US
Patent application number | Description | Published |
---|---|---|
20110045053 | ISOLATED POPULATION OF LUMINAL STEM CELLS THAT GIVE RISE TO PROSTATE CANCER AND METHODS OF USING SAME - The present invention is directed to an isolated population of luminal stem cells obtained from the prostate epithelium that express Nkx3.1. The invention is also directed to methods for diagnosing whether a patient is at risk of developing prostate cancer. | 02-24-2011 |
Corrine T. Abate-Shen, Warren, NJ US
Patent application number | Description | Published |
---|---|---|
20080216180 | Animal model for cancer, methods of producing the same and associated methods of use - A transgenic animal having a somatic cell in which at least one allele of an endogenous p53 and Pten gene is functionally disrupted is provided. The cell of the animal may be heterozygous or, more preferably, homozygous for the gene disruptions. The animals of the invention can be used to evaluate the efficacy of novel therapeutics and to identify novel points of therapeutic intervention for cancer. In certain embodiments, the transgenic animal is a transgenic mouse having functionally disrupted endogenous p53 and Pten genes. This mouse can be used to identify agents that inhibit the development of cancers, namely bladder cancers in humans in vivo. Nucleic acid constructs for functionally disrupting an endogenous p53 and Pten gene in a host cell, recombinant vectors including the nucleic acid construct, and host cells into which the nucleic acid construct has been introduced are also encompassed by the invention | 09-04-2008 |